Please Wait.....
Report
HIV Diagnosis Market By Mode (Self-test, Lab-based), By Test Type (Antibody/Antigen Test, Viral load test/Nucleic Acid Test, CD4 test, Test for Early Infant Diagnosis), By End-use (Diagnostic Laboratories, Hospitals and Clinics, Home Settings): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2024-02-01 I 290 Pages I Allied Market Research
The global HIV diagnosis market was valued at $1.9 billion in 2022, and is projected to reach $2.7 billion by 2032, growing at a CAGR of 3.9% from 2023 to 2032.
It is a procedure that determines if a person has contracted the Human Immunodeficiency Virus (HIV), a virus that leads to acquired immunodeficiency syndrome (AIDS). Several approaches and methodologies are used in HIV testing to establish whether an individual has HIV antibodies, antigens, or gene (RNA or DNA) in his blood volumes, saliva, and urine. Essentially, the focus of HIV testing is aimed at detecting infected persons very early, offering them relevant medical attention as well as preventing others from acquiring the infection.
Trends in HIV diagnosis exhibit a diverse landscape shaped by factors including geographical location, demographics, prevention measures, and healthcare accessibility. Notably, several high-income countries with robust prevention and treatment programs have witnessed a decline in new HIV diagnoses due to heightened awareness, widespread testing, improved treatment access, and preventive strategies such as Pre-exposure prophylaxis (PrEP). For instance, in 2022, according to Organization for Economic Cooperation and Development (OECD) in Asia-Pacific, the prevalence of HIV infection varied importantly, ranging from less than 0.1% of adults aged 15 to 49 in Bangladesh, Mongolia, New Zealand, and Sri Lanka to 1% of adults aged 15 to 49 in Thailand in 2020. Although HIV prevalence was low, the absolute number of people living with HIV was high at more than 2.2 million in reporting countries and territories in 2021, owing to Asia-Pacific's large population.
Although there have been advancements in the prevention and treatment of HIV, it is important to note that some specific populations such as men who have sexual intercourse with other men (MSM), transgender people, and racial minorities continue to report high rates of HIV diagnoses. These disparities underscore prevailing inequalities in care. At the same time, new HIV epidemics are emerging within certain populations or regions, owing to factors such as injecting drugs and difficulties in accessing healthcare services. Young people also remain vulnerable in certain areas such as sub-Saharan Africa as they lack adequate sex education and limited access to health care.
The HIV diagnosis market is segmented into mode, test type, end use, and region. By mode, the market is segregated into self-test and lab based. By test type the market is segregated into antibody/antigen test, viral load test/nucleic acid test, CD4 test, and test for early infant diagnosis. Antibody/antigen test is further segregated into HIV-1 screening tests, HIV-1 antibody confirmatory tests, and HIV-2 & Group Of diagnostic tests. By end use, the market is segregated into diagnostic laboratories, hospitals & clinics, and home settings. By region, the HIV diagnosis market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
Major companies operating in this market include Abbott, Gilead Sciences, Inc., Merck & Co. Inc., Beckman Coulter, Inc., Mylan N.V., F. Hoffman-La Roche Ltd., Siemens Healthcare GmbH, QIAGEN, Bio-Rad Laboratories, Inc., and Hologic.Key players have adopted product launch and collaboration as their key strategy to improve the product portfolio of the testosterone replacement therapy market.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv diagnosis market analysis from 2022 to 2032 to identify the prevailing hiv diagnosis market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the hiv diagnosis market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global hiv diagnosis market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Criss-cross segment analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Market share analysis of players at global/region/country level
- SWOT Analysis
Key Market Segments
By Mode
- Self-test
- Lab-based
By Test Type
- Antibody/Antigen Test
- Type
- HIV-1 Screening Tests
- HIV-1 Antibody Confirmatory Tests
- HIV-2 and Group O Diagnostic Tests
- Viral load test/Nucleic Acid Test
- CD4 test
- Test for Early Infant Diagnosis
By End-use
- Diagnostic Laboratories
- Hospitals and Clinics
- Home Settings
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Abbott Laboratories
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- Danaher Corporation
- Mylan N.V.
- F Hoffman La Roche Ltd
- Siemens Healthcare Private Limited
- Qiagen NV.
- Bio-Rad Laboratories, Inc.
- Hologic Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HIV DIAGNOSIS MARKET, BY MODE
4.1. Overview
4.1.1. Market size and forecast
4.2. Self-test
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Lab-based
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: HIV DIAGNOSIS MARKET, BY TEST TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Antibody/Antigen Test
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Antibody/Antigen Test HIV Diagnosis Market by Type
5.3. Viral load test/Nucleic Acid Test
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. CD4 test
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Test for Early Infant Diagnosis
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: HIV DIAGNOSIS MARKET, BY END-USE
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic Laboratories
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Hospitals and Clinics
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Home Settings
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: HIV DIAGNOSIS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Mode
7.2.3. Market size and forecast, by Test Type
7.2.4. Market size and forecast, by End-use
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Mode
7.2.5.1.2. Market size and forecast, by Test Type
7.2.5.1.3. Market size and forecast, by End-use
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Mode
7.2.5.2.2. Market size and forecast, by Test Type
7.2.5.2.3. Market size and forecast, by End-use
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Mode
7.2.5.3.2. Market size and forecast, by Test Type
7.2.5.3.3. Market size and forecast, by End-use
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Mode
7.3.3. Market size and forecast, by Test Type
7.3.4. Market size and forecast, by End-use
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Mode
7.3.5.1.2. Market size and forecast, by Test Type
7.3.5.1.3. Market size and forecast, by End-use
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Mode
7.3.5.2.2. Market size and forecast, by Test Type
7.3.5.2.3. Market size and forecast, by End-use
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Mode
7.3.5.3.2. Market size and forecast, by Test Type
7.3.5.3.3. Market size and forecast, by End-use
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Mode
7.3.5.4.2. Market size and forecast, by Test Type
7.3.5.4.3. Market size and forecast, by End-use
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Mode
7.3.5.5.2. Market size and forecast, by Test Type
7.3.5.5.3. Market size and forecast, by End-use
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Mode
7.3.5.6.2. Market size and forecast, by Test Type
7.3.5.6.3. Market size and forecast, by End-use
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Mode
7.4.3. Market size and forecast, by Test Type
7.4.4. Market size and forecast, by End-use
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Mode
7.4.5.1.2. Market size and forecast, by Test Type
7.4.5.1.3. Market size and forecast, by End-use
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Mode
7.4.5.2.2. Market size and forecast, by Test Type
7.4.5.2.3. Market size and forecast, by End-use
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Mode
7.4.5.3.2. Market size and forecast, by Test Type
7.4.5.3.3. Market size and forecast, by End-use
7.4.5.4. India
7.4.5.4.1. Market size and forecast, by Mode
7.4.5.4.2. Market size and forecast, by Test Type
7.4.5.4.3. Market size and forecast, by End-use
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Mode
7.4.5.5.2. Market size and forecast, by Test Type
7.4.5.5.3. Market size and forecast, by End-use
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Mode
7.4.5.6.2. Market size and forecast, by Test Type
7.4.5.6.3. Market size and forecast, by End-use
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Mode
7.5.3. Market size and forecast, by Test Type
7.5.4. Market size and forecast, by End-use
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Mode
7.5.5.1.2. Market size and forecast, by Test Type
7.5.5.1.3. Market size and forecast, by End-use
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Mode
7.5.5.2.2. Market size and forecast, by Test Type
7.5.5.2.3. Market size and forecast, by End-use
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Mode
7.5.5.3.2. Market size and forecast, by Test Type
7.5.5.3.3. Market size and forecast, by End-use
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Mode
7.5.5.4.2. Market size and forecast, by Test Type
7.5.5.4.3. Market size and forecast, by End-use
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Gilead Sciences, Inc.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Merck & Co. Inc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Danaher Corporation
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Mylan N.V.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. F Hoffman La Roche Ltd
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Siemens Healthcare Private Limited
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Qiagen NV.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Bio-Rad Laboratories, Inc.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Hologic Inc.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 02. HIV DIAGNOSIS MARKET FOR SELF-TEST, BY REGION, 2022-2032 ($MILLION)
TABLE 03. HIV DIAGNOSIS MARKET FOR LAB-BASED, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 05. HIV DIAGNOSIS MARKET FOR ANTIBODY/ANTIGEN TEST, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL ANTIBODY/ANTIGEN TEST HIV DIAGNOSIS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 07. HIV DIAGNOSIS MARKET FOR VIRAL LOAD TEST/NUCLEIC ACID TEST, BY REGION, 2022-2032 ($MILLION)
TABLE 08. HIV DIAGNOSIS MARKET FOR CD4 TEST, BY REGION, 2022-2032 ($MILLION)
TABLE 09. HIV DIAGNOSIS MARKET FOR TEST FOR EARLY INFANT DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 11. HIV DIAGNOSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. HIV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. HIV DIAGNOSIS MARKET FOR HOME SETTINGS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. HIV DIAGNOSIS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA HIV DIAGNOSIS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 20. U.S. HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 22. CANADA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 23. CANADA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 25. MEXICO HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 26. MEXICO HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 28. EUROPE HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 29. EUROPE HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 31. EUROPE HIV DIAGNOSIS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 33. GERMANY HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 35. FRANCE HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 36. FRANCE HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 38. UK HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 39. UK HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 40. UK HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 41. ITALY HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 42. ITALY HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 44. SPAIN HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 45. SPAIN HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 55. JAPAN HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 57. CHINA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 58. CHINA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 63. INDIA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 64. INDIA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 65. INDIA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 72. LAMEA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 73. LAMEA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 75. LAMEA HIV DIAGNOSIS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 77. BRAZIL HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA HIV DIAGNOSIS MARKET, BY MODE, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA HIV DIAGNOSIS MARKET, BY END-USE, 2022-2032 ($MILLION)
TABLE 88. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 89. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 90. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 91. ABBOTT LABORATORIES: SERVICE SEGMENTS
TABLE 92. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 93. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 94. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 95. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 96. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 97. GILEAD SCIENCES, INC.: SERVICE SEGMENTS
TABLE 98. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 99. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 102. MERCK & CO. INC.: PRODUCT SEGMENTS
TABLE 103. MERCK & CO. INC.: SERVICE SEGMENTS
TABLE 104. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 105. MERCK & CO. INC.: KEY STRATERGIES
TABLE 106. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 107. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 108. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 109. DANAHER CORPORATION: SERVICE SEGMENTS
TABLE 110. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 111. DANAHER CORPORATION: KEY STRATERGIES
TABLE 112. MYLAN N.V.: KEY EXECUTIVES
TABLE 113. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 114. MYLAN N.V.: PRODUCT SEGMENTS
TABLE 115. MYLAN N.V.: SERVICE SEGMENTS
TABLE 116. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 117. MYLAN N.V.: KEY STRATERGIES
TABLE 118. F HOFFMAN LA ROCHE LTD: KEY EXECUTIVES
TABLE 119. F HOFFMAN LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 120. F HOFFMAN LA ROCHE LTD: PRODUCT SEGMENTS
TABLE 121. F HOFFMAN LA ROCHE LTD: SERVICE SEGMENTS
TABLE 122. F HOFFMAN LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 123. F HOFFMAN LA ROCHE LTD: KEY STRATERGIES
TABLE 124. SIEMENS HEALTHCARE PRIVATE LIMITED: KEY EXECUTIVES
TABLE 125. SIEMENS HEALTHCARE PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 126. SIEMENS HEALTHCARE PRIVATE LIMITED: PRODUCT SEGMENTS
TABLE 127. SIEMENS HEALTHCARE PRIVATE LIMITED: SERVICE SEGMENTS
TABLE 128. SIEMENS HEALTHCARE PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 129. SIEMENS HEALTHCARE PRIVATE LIMITED: KEY STRATERGIES
TABLE 130. QIAGEN NV.: KEY EXECUTIVES
TABLE 131. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 132. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 133. QIAGEN NV.: SERVICE SEGMENTS
TABLE 134. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 135. QIAGEN NV.: KEY STRATERGIES
TABLE 136. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 137. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 138. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 139. BIO-RAD LABORATORIES, INC.: SERVICE SEGMENTS
TABLE 140. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 141. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 142. HOLOGIC INC.: KEY EXECUTIVES
TABLE 143. HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 144. HOLOGIC INC.: PRODUCT SEGMENTS
TABLE 145. HOLOGIC INC.: SERVICE SEGMENTS
TABLE 146. HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 147. HOLOGIC INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. HIV DIAGNOSIS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF HIV DIAGNOSIS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN HIV DIAGNOSIS MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN HIV DIAGNOSIS MARKET (2023-2032)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL HIV DIAGNOSIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. HIV DIAGNOSIS MARKET, BY MODE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR SELF-TEST, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR LAB-BASED, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. HIV DIAGNOSIS MARKET, BY TEST TYPE, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR ANTIBODY/ANTIGEN TEST, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR VIRAL LOAD TEST/NUCLEIC ACID TEST, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR CD4 TEST, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR TEST FOR EARLY INFANT DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. HIV DIAGNOSIS MARKET, BY END-USE, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HIV DIAGNOSIS MARKET FOR HOME SETTINGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. HIV DIAGNOSIS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 24. U.S. HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 33. JAPAN HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 34. CHINA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 36. INDIA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF ASIA-PACIFIC HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 39. BRAZIL HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SAUDI ARABIA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF LAMEA HIV DIAGNOSIS MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: HIV DIAGNOSIS MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security